Comparative Pharmacology
Head-to-head clinical analysis: LUSEDRA versus SOLIFENACIN SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUSEDRA versus SOLIFENACIN SUCCINATE.
LUSEDRA vs SOLIFENACIN SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
Solifenacin is a competitive muscarinic receptor antagonist. It binds selectively to M3 muscarinic receptors, inhibiting acetylcholine action on smooth muscle of the urinary bladder, reducing detrusor overactivity and increasing bladder capacity.
5 mg orally once daily.
5 mg orally once daily, may increase to 10 mg once daily if tolerated.
None Documented
None Documented
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Terminal elimination half-life is approximately 45-68 hours (mean ~55 hours) in healthy adults, allowing once-daily dosing.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Primarily renal: ~69% as metabolites (including active metabolite 4R-hydroxy solifenacin) and ~7% as unchanged drug. Fecal excretion accounts for ~23% (mainly as metabolites).
Category C
Category A/B
Anticholinergic
Anticholinergic